Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Shares of Soleno Therapeutics (NASDAQ:SLNO) fell by 6.7% after insider selling. Highlights:,Insider transactions have been ...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...
Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...
Equities researchers at Cantor Fitzgerald lowered their FY2025 EPS estimates for Soleno Therapeutics in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska ...
We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...
Explore more
We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...
We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to ...
Stock futures inched up on Thursday as investors assessed President Donald Trump’s 25% tariff on foreign cars, which is set to take effect next week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results